Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00302016
First received: March 9, 2006
Last updated: August 25, 2011
Last verified: August 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
No publications provided by Novartis

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):